Astaxanthin

Why brands use Astaxanthin

Astaxanthin is a supplement input commonly considered across multiple positionings, sitting in the other family. On DAT Supply briefs the positioning is set by the brand brief and reviewed against the target market’s claim rules — we do not pre-position an active for any single benefit. Editorial framing uses only EU 432/2012- or DSHEA-compatible wording — we never promote unauthorised claims, even when the active has consumer-side momentum. Format-wise we have considered Astaxanthin for gummies; the per-format formulation notes below describe the live constraints (taste, payload, stability, packaging) we tune in the formulation pass. Sourcing form (extract ratio for botanicals, salt or chelate form for minerals, free-form vs ester for amino acids) is reviewed against the brief, with documentation matched to the target market’s import rules. Inclusion rate and claim wording are reviewed per project — we don’t publish off-the-shelf doses.

How we use Astaxanthin in formulas

A public-safe formulation reference — how this active behaves in our formats, common pairings and handling notes. Final formulation, dose and on-pack copy are confirmed per project.

Heat stable

Limited — use coated forms

Soluble in matrix

Conditional

Vegan supply

Project-specific

EU-authorised health claims

EU-authorised wording for this ingredient is reviewed per project against Reg. 1924/2006 and the authorised list under Reg. 432/2012. No final claim wording is implied by this page.

Astaxanthin is reviewed against the target market’s claim posture: in the EU we check the 432/2012 authorised list and any country-level rules; UK rules track EU post-Brexit. For the US market, DSHEA structure-function wording applies with the FDA disclosure. We do not reuse EU wording on a US label or vice versa — pack copy is rewritten per market and confirmed per project.